The Centre has announced a ban on the manufacture, sale, distribution, and supply of 16 fixed-dose combination (FDC) drugs for human use across India, citing a lack of “therapeutic justification” for these medications. This ban is effective immediately and aims to protect public health by promoting the rational use of medicines and ensuring access to only scientifically validated medications.

The Union Health Ministry stated that this decision aligns with its commitment to public health and verifies that continuing to use these combinations is not deemed beneficial considering the associated risks. The Ministry’s actions follow a detailed review process initiated at the directive of the Supreme Court.

In response to the acute need for regulatory oversight, the Drugs Technical Advisory Board formed an expert committee tasked with evaluating various FDCs. The committee focused on identifying drug combinations that were irrational or could potentially cause harm to patients.

Details of the Banned Combinations

According to the notification issued under Section 26A of the Drugs and Cosmetics Act, 1940, the prohibition includes various therapeutic categories. Notably, the banned formulations include certain dermatological preparations, analgesic and antispasmodic medicines, as well as antibiotic-based combinations.

Among the specific drugs listed for prohibition are combinations such as Acetyl Salicylic Acid with Ethoheptazine, Dicyclomine, Paracetamol with Clidinium Bromide, Gliclazide with Chromium Picolinate, and Paracetamol with Lignocaine. The prohibition also covers multiple antibiotic combinations, including Amoxicillin with Serratiopeptidase and Amoxicillin with Cloxacillin.

Skin care formulations that include ingredients like Aloe Vera, Vitamin E, and Tea Tree Oil in unapproved combinations also feature in the banned list. This broad categorisation underscores the Ministry’s focus on ensuring only safe and effective treatments are accessible to the public.

Government’s Commitment to Rational Medicine Use

The Ministry has emphasised that this decision is part of ongoing efforts to enhance patient safety and encourage the rational use of medications in healthcare settings. Several irrational FDCs had previously been prohibited after comprehensive scientific evaluation, highlighting the government’s proactive approach to drug regulation.

All state drug controllers, regulatory authorities, and enforcement agencies have been instructed to enforce this ban rigorously. The Ministry also advises manufacturers and other stakeholders in the pharmaceutical chain to take corrective measures in compliance with the new regulations.

This latest move by the Centre is aimed at ensuring that only effective and validated medicines remain in circulation, thereby safeguarding public health and reinforcing trust in the healthcare system. The government recognises the importance of rigorous science-based evaluations to eliminate potentially harmful drug combinations from the market.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share